Migraine and increased cardiovascular disease risk: interaction with traditional risk factors and lifestyle factors
Abstract
BACKGROUND: Migraine has been linked to a heightened risk of cardiovascular disease, and acute treatment drugs, such as triptans, might increase this risk. This study aimed to determine whether the elevated cardiovascular risk is primarily attributable to the underlying migraine condition or the treatment modalities utilized. Additionally, we investigated the effects of managing traditional cardiovascular risk factors and the influence of healthy lifestyle scores on this association.
METHODS: This population-based investigation leveraged data from the UK Biobank, encompassing participants recruited between 2006 and 2010, to examine the association between migraine and the long-term risk of atherosclerotic cardiovascular disease and its subtypes. Cox proportional hazard models were employed to conduct this analysis. Furthermore, the study evaluated the relative importance of migraine in predicting atherosclerotic cardiovascular disease by calculating the R² values of the Cox models. Additionally, multiplicative and additive interaction analyses were conducted to examine whether the association between migraine and cardiovascular disease varies based on the degree of risk factor control and lifestyle scores.
RESULTS: Across an average follow-up span of 12.9 years, a total of 24,038 cardiovascular events were documented, comprising 12,451 cases of coronary heart disease, 3,608 cases of ischemic stroke, and 4,493 cases of peripheral artery disease. In a thoroughly adjusted…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.